Hydroxamate-based inhibitors of deacetylases B

Details Hydroxamate-based inhibitors of deacetylases B Hydroxamate-based inhibitors of deacetylases B

2011-05-17

2011-05-17

Saeed, Kamal A (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S406000, C548S360100, C548S364100

Reexamination Certificate

active

07943652

ABSTRACT:
The present teachings relate to compounds of Formula I:and pharmaceutically acceptable salts, hydrates, esters, and prodrugs thereof, wherein R1, R2, R3, Y, Z, andare as defined herein.The present teachings also provide methods of preparing compounds of Formula I and methods of using compounds of Formula I in treating, inhibiting, or preventing pathologic conditions or disorders mediated wholly or in part by deacetylases.

REFERENCES:
patent: 2010/0069318 (2010-03-01), Atadja
patent: 2010/0179208 (2010-07-01), Atadja et al.
patent: WO 02/22577 (2002-03-01), None
patent: WO 2004/063169 (2004-07-01), None
patent: WO 2005/013958 (2005-02-01), None
patent: WO 2005/014004 (2005-02-01), None
patent: WO 2007/030454 (2007-03-01), None
patent: WO 2007/030455 (2007-03-01), None
patent: WO 2008/014114 (2008-11-01), None
Vippagunta et al., Crystalline solids, 2001, Advanced Drug Delivery Reviews, 48, pp. 3 and 18.
Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, 1999, Science, vol. 286, pp. 531-537.
Lala et al., Role of nitric oxide in tumor progression: Lessons from experimental tumors, 1998, Cancer and Metastasis Reviews,17(1 ), pp. 91-106.

Affiliated with

Also associated with

Rating

Hydroxamate-based inhibitors of deacetylases B does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydroxamate-based inhibitors of deacetylases B, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxamate-based inhibitors of deacetylases B will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2673854